SCHEMBL5889046

SCHEMBL5889046

Nc1cc(N2CCC(N)CC2)ncn1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 2/20 0.52
KDR P35968 3/20 0.50
HRH3 Q9Y5N1 1/20 0.50
RIPK1 Q13546 2/20 0.44
HRH4 Q9H3N8 1/20 0.44
AKT1 P31749 3/20 0.43
HTR3E A5X5Y0 1/20 0.42
MEN1 O00255 1/20 0.42
HTR3B O95264 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2D6 P10635 1/20 0.42
ALOX15 P16050 1/20 0.42
TSHR P16473 1/20 0.42
NFKB1 P19838 1/20 0.42
HTR3A P46098 1/20 0.42
KMT2A Q03164 1/20 0.42
HTR3D Q70Z44 1/20 0.42
HTR3C Q8WXA8 1/20 0.42
AKT2 P31751 4/20 0.42
KIT P10721 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5889171 0.94 KDR (0.54) CHEK1KDRHRH3RIPK1HRH4
SCHEMBL23024919 0.84 RIPK1 (0.46) CHEK1KDRRIPK1AKT1GSK3B
SCHEMBL807296 0.81 SMN1; SMN2 (0.50) HRH4AKT1TSHR
SCHEMBL30579439 0.81 SMN1; SMN2 (0.50) HRH4AKT1TSHR
SCHEMBL19004851 0.81 AKT1 (0.47) RIPK1HRH4AKT1TSHR
SCHEMBL29442361 0.81 CHEK1 (0.48) CHEK1KDRHRH3HRH4AKT1
SCHEMBL16854339 0.81 HTR3E (0.53) CHEK1KDRHRH3HRH4AKT1
SCHEMBL2270340 0.81 CHEK1 (0.48) CHEK1KDRHRH3HRH4AKT1
SCHEMBL5889085 0.79 SMN1; SMN2 (0.53) HRH4AKT1CYP1A2TSHRKMT2A
Hydrochloric Acid SCHEMBL2270339 0.79 CHEK1 (0.47) CHEK1KDRHRH3HRH4AKT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7115597-B2 Tyrosine kinase inhibitors MERCK & CO., INC. (US) 2006-10-03 US disclosed
US-20040063720-A1 Tyrosine kinase inhibitors MERCK & CO., INC. 2004-04-01 US disclosed
EP-1341540-A2 TYROSINE KINASE INHIBITORS Merck & Co., Inc. (US) 2003-09-10 EP disclosed
US-20020137755-A1 Tyrosine kinase inhibitors BILODEAU MARK T (US) 2002-09-26 US disclosed
WO-2002045652-A2 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2002-06-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020137755-A1 Tyrosine kinase inhibitors ERBB2, TYRO3, TIE1 CHEK1 499/4885KDR 5/4885HRH3 3514/4885
US-20040063720-A1 Tyrosine kinase inhibitors ERBB2, TYRO3, TIE1 CHEK1 499/4885KDR 5/4885HRH3 3514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.